At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed locally advanced or metastatic (Stage IIIB-IV) NSCLC
- ✓Prior treatment with an EGFR tyrosine kinase inhibitor (TKI)
- ✕Prior chemotherapy, surgery, or systemic anti-cancer therapy within 4 weeks before study start
- ✕Three or more prior chemotherapy regimens
- ✕Significant cardiovascular events
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer After Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)
In Brief
A Phase 3 clinical trial evaluating ZD6474 (vandetanib) and Best Supportive Care for Non-Small-Cell Lung Carcinoma. Completed, enrolled 1,140 participants across 102 sites in 22 countries.
Detailed Summary
This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred after previous chemotherapy and an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI). ZD6474 is a new anti-cancer drug in development that works in a different way to standard chemotherapy drugs. It targets the growth of new blood vessels to a tumour and thereby might slow the rate at which the tumour may grow. Early studies indicate that ZD6474 has a positive effect on the time that a tumour may take to progress to a further stage. Approximately 930 patients will take part in this study. It will be conducted in hospitals and clinics in North and South America, Europe and Asia.
Study Details
Timeline
Interventions
once daily oral tablet
standard of care